Piramal deal will give Abbott India size Piramal, who is the chairman of Piramal Healthcare, said “the valuation of about nine times shows the. It took four hours for Ajay Piramal to negotiate a whopping $ billion valuation for his generics business with Abbott. Just how did he pull it off. Abbott to pay $ billion for unit of India’s Piramal Disagreements over valuation have prevented more deals from getting done. Abbott.
|Published (Last):||13 January 2015|
|PDF File Size:||19.94 Mb|
|ePub File Size:||6.92 Mb|
|Price:||Free* [*Free Regsitration Required]|
As a global MNC, Abbott does. The earlier regime recognized patents on pharmaceutical processes but not on pharmaceutical products, allowing companies to reverse-engineer copies of the branded and patented drugs of western companies.
Chaudhuri acknowledges those new realities, but with a patriotic tinge. Indian companies can hope to become truly global pharmaceutical companies abboth through drug discovery, says Piramal.
That is one reason pharmaceutical multinationals are doing deals with the relatively small number of well established Indian companies that have met international standards in manufacturing. Globally, Abbott also faces the pressure of playing catch-up with its bigger rivals. The stigma of selling—that has been holding back promoters of Indian pharmaceutical companies—is gone after two large lucrative deals in the sector, said an investment banker who asked not to be named.
A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma?
Abbott plans to fund the deal with cash on its balance sheet and said it would not change its earnings outlook for Foul language Slanderous Inciting hatred against a certain community Others. Mumbai-based Piramal said it would consider paying a special dividend and would use deal proceeds to invest in its remaining businesses and pay down debt. The potential to expand with very high priced specialty products is seriously limited. Globalization is not just for manufacturers. Piramal Healthcare also retains custom manufacturing, over-the-counter consumer products, diagnostic medical devices and services and clinical research, among other activities.
Several other deals occurred over the past one year. Many view private equity firms as villainous actors intent on the singular goal of abboott. For consumers, the great value in generics is getting it cheaper. It is increasingly a preferred choice for infrastructure and real estate developers as well.
A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma? – [email protected]
As part of the deal, around 5, Piramal employees and one manufacturing facility in Baddi, Himachal Pradesh will pirzmal transferred to Abbott. Are you a Business Owner? Sumeet ChatterjeeBharghavi Nagaraju. Will be displayed Will not be displayed Will be displayed. Abbott has been operating in India for of its years, and has popular pharmaceutical brands including the antacid Digene and painkiller Brufen.
Abbott said it was advised by Morgan Stanley, while Piramal said it did not have a financial advisor on the deal.
In fact, qbbott days before the Piramal acquisition, Abbott announced a licensing and supply deal with Indian pharmaceutical company Zydus Cadila. By comparison, Cipla trades at about 4.
Abbott to pay $ billion for unit of India’s Piramal | Reuters
My Saved Articles Sign in Sign up. Of its brands sold on Friday, at least 48 valuafion sales of more than Rs 10 crore a year and are marketed by a sales force of 4, who reach more than 2. On top of that, India is a growing market.
Increased funding expands the scope for drug research, but that alone is not enough; other pieces have to fall in place, Piramal notes. Danzon adds that the emerging business plan for generics companies is essentially around selling to pharmacists, not physicians.
Find this comment offensive? Food and Drug Administration said in February Ranbaxy sold misbranded or adulterated drugs in the United States, its largest market, having earlier banned imports of over 30 generic drugs from the firm.
Your Reason has been Reported to the admin. Additional Reading Management Finding the Virtue in Private Equity Firms Many view private equity firms as villainous actors intent on the singular goal of profit.
This is no different for Chinese firms. According to Wharton faculty and industry experts, changing global business models and the resources needed to develop blockbuster drugs are propelling Indian companies to join forces with multinationals through strategic alliances or as targets for acquisitions.
Get instant notifications from Economic Times Allow Not now. Now, Piramal on its own has that opportunity. Danzon points to Dr. Expensive legal battles with patent holders, higher regulatory scrutiny after charges of poor manufacturing quality, and increased competition in the generics space have compelled Indian pharmaceuticals firms to look for buyers. But that is also changing, she says.